TY - JOUR T1 - Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis JF - BMJ Open Gastroenterology DO - 10.1136/bmjgast-2016-000127 VL - 4 IS - 1 SP - e000127 AU - Johannes Bethge AU - Silvia Meffert AU - Mark Ellrichmann AU - Claudio Conrad AU - Susanna Nikolaus AU - Stefan Schreiber Y1 - 2017/02/01 UR - http://bmjopengastro.bmj.com//content/4/1/e000127.abstract N2 - Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA. ER -